100 results
DRS/A
EX-10
CHRS
Coherus Biosciences Inc
5 Aug 14
Draft registration statement (amended)
12:00am
, United States of America (“BII”), Baxter Healthcare SA, a Swiss corporation with a principal place of business at Postfach 8010 Zurich, Switzerland … (“BHSA”) and Baxter Healthcare Corporation, a Delaware corporation with a principal place of business at 1 Baxter Parkway, Deerfield, IL 60015, United
8-K
CHRS
Coherus Biosciences Inc
14 Apr 20
Entry into a Material Definitive Agreement
7:43am
, HealthCare Royalty Partners III, L.P. (“HCR”), MX II Associates LLC, KMG Capital Partners, LLC and KKR Biosimilar L.P., each as an investor, and certain … factors, healthcare providers, payers and patients not utilizing or adopting UDENYCA® due to resources being strained or otherwise focused on the COVID
10-Q/A
2015 Q1
CHRS
Coherus Biosciences Inc
29 Jun 15
Quarterly report (amended)
12:00am
Agreement, effective April 10, 2015, by and among Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA and Coherus … 10, 2015, by and among Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA and Coherus BioSciences, Inc.
10-Q
10.2
8-K
CHRS
Coherus Biosciences Inc
10 May 22
Departure of Directors or Certain Officers
4:58pm
Director & Co-Head of Healthcare Investment Banking in the Americas at BofA Securities, Managing Director & Co-Head of Healthcare Investment Banking … in the Americas at Credit Suisse, and Managing Director & Head of Western Region Healthcare Investment Banking at Morgan Stanley. Mr. Newton advised
8-K
EX-10.2
0ew2 r43dd
14 Apr 20
Entry into a Material Definitive Agreement
7:43am
8-K
EX-99.1
xxk0x9xbuyu0qo0
10 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
zs8dq1p hnm
7 Jan 21
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
4:15pm
8-K
EX-99.1
a9j4pxh36r qhh011
3 May 19
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-99.1
s4iaqkppz9q06url4w0m
6 Aug 20
Coherus BioSciences Reports Second Quarter 2020 Financial Results
4:07pm
8-K
m3b5o2nl41e9ijg
10 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
oqprcu9iojymv5t52xk
14 Apr 20
Entry into a Material Definitive Agreement
7:43am
DRS
EX-10.14
ywgtds
4 Aug 14
Draft registration statement
12:00am